USA’s National Institute of Allergy and Infectious Diseases also called the NIAID, has developed an experimental vaccine to combat the dreaded dengue virus. Reports state that the vaccine has provided protection to all the people who were included in the clinical trial carried out by the institute. 
Nearly 21 people were included in the trial conducted by the NIAID, and they were given the TV003 vaccine, on the other hand about 20 people were administered a placebo. The 21 people who were vaccinated with the TV003 remained protected against the infection and 20 people who had been given the placebo got the dengue infection.
A generally weakened version of dengue virus was prepared in the same way as the scientists did it for flu, measles and mumps and the scientists named it as TV003 – the live vaccine. The volunteers who were given the vaccine showed mild rash like symptoms but no significant ill effects were noticed. The mild rash disappeared in about 5-10 days and the bodies of the subjects started to develop antibodies against dengue. TV003 has a blend of “four recombinant dengue vaccine candidate viruses, designed to combat all four major dengue virus serotypes” say the reports.
The vector borne infection is prevalent in subtropical and tropical regions and includes Asia, Caribeean, Central America, Africa, and South America. The Dengue virus is spread by the “daytime” Aedes mosquito.
Ph.D., of the NIAID, Dr. Stephen Whitehead, had created the dengue-2 challenge virus that had also caused a mild illness in previous studies, and the same virus has been used for this trial. The same challenge virus had led to viremia and a mild rash in the recipient earlier and the virus had been detected in the blood.
